Published in PLoS One on May 25, 2012
Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet (2014) 1.31
Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor. PLoS One (2013) 0.93
Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells. Mol Cancer (2013) 0.86
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions. Drugs (2015) 0.83
Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials. Onco Targets Ther (2014) 0.80
Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas. PLoS One (2015) 0.80
FAM96A is a novel pro-apoptotic tumor suppressor in gastrointestinal stromal tumors. Int J Cancer (2015) 0.79
Targeting Disease Persistence in Gastrointestinal Stromal Tumors. Stem Cells Transl Med (2015) 0.77
Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imaging. Cancer Biol Ther (2014) 0.77
Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy. BMC Cancer (2015) 0.76
Cell cycle and dystrophin dysregulation in GIST. Cell Cycle (2015) 0.75
Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors. Genes Chromosomes Cancer (2016) 0.75
MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nat Commun (2017) 0.75
ETV1-positive cells give rise to BRAFV600E mutant gastrointestinal stromal tumors. Cancer Res (2017) 0.75
Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions. Oncotarget (2017) 0.75
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 11.11
Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc (2006) 8.42
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol (2008) 6.43
p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell (2000) 5.64
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res (2001) 5.40
The MDM2 gene amplification database. Nucleic Acids Res (1998) 4.64
Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol (1999) 4.48
The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol (2003) 4.46
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem (1998) 3.80
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene (2001) 3.36
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res (2006) 3.00
MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell (2009) 2.36
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res (2006) 2.04
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer (2008) 1.99
KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene (2007) 1.84
Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene (2004) 1.82
Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle (2010) 1.75
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer (2005) 1.73
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene (2007) 1.59
Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol (2001) 1.55
Transcription, apoptosis and p53: catch-22. Trends Genet (2005) 1.39
Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res (2005) 1.22
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res (2009) 1.18
Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol (2009) 1.18
p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation. Cell Death Differ (2003) 1.16
HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. Cancer Res (2009) 1.15
Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res (2009) 1.14
Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation. Oncogene (2003) 1.07
p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation. Oncogene (2010) 1.06
Adult pancreas generates multipotent stem cells and pancreatic and nonpancreatic progeny. Stem Cells (2004) 1.01
Regulation of p53: intricate loops and delicate balances. Ann N Y Acad Sci (2002) 1.01
The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer (2005) 1.00
Patterns of gene amplification in gastrointestinal stromal tumors (GIST). Lab Invest (2005) 0.99
Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway. Apoptosis (2010) 0.94
STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1. Cancer Sci (2005) 0.92
Homogeneous time-resolved fluorescence quenching assay (LANCE) for caspase-3. J Biomol Screen (2002) 0.91
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol (2013) 11.68
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 11.11
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science (2004) 9.52
The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease. Am J Hum Genet (2008) 8.78
Walking the interactome for prioritization of candidate disease genes. Am J Hum Genet (2008) 7.03
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol (2008) 6.43
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol (2006) 6.00
Biology of gastrointestinal stromal tumors. J Clin Oncol (2004) 5.89
The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Res (2013) 5.66
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science (2008) 5.30
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA (2012) 5.00
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med (2015) 4.78
Improved detection of overrepresentation of Gene-Ontology annotations with parent child analysis. Bioinformatics (2007) 4.32
BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res (2003) 4.17
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
Identity-by-descent filtering of exome sequence data identifies PIGV mutations in hyperphosphatasia mental retardation syndrome. Nat Genet (2010) 3.60
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol (2007) 3.38
Concern The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist (2003) 3.36
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Clinical diagnostics in human genetics with semantic similarity searches in ontologies. Am J Hum Genet (2009) 3.01
Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci U S A (2010) 3.00
Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol (2004) 2.92
Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol (2002) 2.85
Nanosize and vitality: TiO2 nanotube diameter directs cell fate. Nano Lett (2007) 2.82
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol (2006) 2.81
Thyroid hormone inactivation in gastrointestinal stromal tumors. N Engl J Med (2014) 2.80
Microindel detection in short-read sequence data. Bioinformatics (2010) 2.73
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A (2010) 2.68
A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol (2008) 2.68
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature (2010) 2.65
KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol (2004) 2.51
Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res (2012) 2.45
Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-independent intrinsic pathway. J Biol Chem (2002) 2.37
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest (2002) 2.31
Gastrointestinal stromal tumors. Virchows Arch (2010) 2.28
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol (2013) 2.25
Improved exome prioritization of disease genes through cross-species phenotype comparison. Genome Res (2013) 2.24
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res (2006) 2.23
Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol (2002) 2.19
Clinical management of uterine sarcomas. Lancet Oncol (2009) 2.18
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Antitumor effects in gastrointestinal stromal tumors using photodynamic therapy with a novel glucose-conjugated chlorin. Mol Cancer Ther (2014) 2.10
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res (2006) 2.04
Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer (2007) 1.99
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res (2009) 1.99
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol (2005) 1.98
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol (2011) 1.95
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res (2007) 1.94
Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol (2007) 1.93
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med (2004) 1.91
Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res (2003) 1.91
The generalised k-Truncated Suffix Tree for time-and space-efficient searches in multiple DNA or protein sequences. Int J Bioinform Res Appl (2008) 1.88
Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell (2003) 1.88
Characterization of the chromosomal translocation t(10;17)(q22;p13) in clear cell sarcoma of kidney. J Pathol (2012) 1.88
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A (2012) 1.86
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol (2012) 1.84
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res (2013) 1.84
Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol (2012) 1.83
Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene (2004) 1.82
Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res (2004) 1.82
USP6 and CDH11 oncogenes identify the neoplastic cell in primary aneurysmal bone cysts and are absent in so-called secondary aneurysmal bone cysts. Am J Pathol (2004) 1.82
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A (2004) 1.81
Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res (2003) 1.81
Conformational control of Bax localization and apoptotic activity by Pro168. J Cell Biol (2004) 1.80
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res (2008) 1.80
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med (2011) 1.79
Positron emission tomography of schwannomas: emphasizing its potential in preoperative planning. AJR Am J Roentgenol (2004) 1.76
Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics (2004) 1.76
Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res (2008) 1.73
Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci U S A (2003) 1.73
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer (2005) 1.73
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet (2006) 1.68
USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Res (2004) 1.64
TiO2 nanotube surfaces: 15 nm--an optimal length scale of surface topography for cell adhesion and differentiation. Small (2009) 1.60
PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol (2002) 1.59
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A (2012) 1.51
Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-α and melphalan. J Surg Oncol (2011) 1.51
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol (2010) 1.48
A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proc Natl Acad Sci U S A (2009) 1.47
Clustering of deletions on chromosome 13 in benign and low-malignant lipomatous tumors. Int J Cancer (2003) 1.45
Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience. Onkologie (2008) 1.45
Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res (2012) 1.43
HMGA2 regulates transcription of the Imp2 gene via an intronic regulatory element in cooperation with nuclear factor-kappaB. Mol Cancer Res (2007) 1.42